Diakonos Oncology

Diakonos Oncology Corp. is a clinical-stage biotechnology company developing immunotherapies to treat challenging cancers. They focus on their proprietary double-loaded, patient-derived dendritic cell therapeutic platform, particularly with the treatment of late-stage and aggressive cancers. Their lead product, dubodencel (DOC1021), is currently in a Phase 2 glioblastoma trial.

Funding Round: SAFE

Funding Amount: $20M

Date: 30-May-2025

Investors: Baylor College of Medicine (BCM), Brain Tumor Investment Fund (BTIF), Buttonwood Titan QC Fund, Mike Wicks

Markets: Biotech, Oncology, Immunotherapy

HQ: Houston, Texas, United States

Founded: 2022

Website: https://www.diakonosoncology.com

LinkedIn: https://www.linkedin.com/company/diakonos-oncology

Twitter: https://x.com/DiakonosOnc

Instagram:

Facebook: